Commentary by Dr. Patrick Smith
With no approved treatments for COVID-19, repurposing existing drugs is an attractive option. But, getting the dose right is more complicated than it might seem. Here’s commentary that was recently published in the British Journal of Clinical Pharmacology: “Dosing will be a key success factor in repurposing antivirals for COVID‐19.”
In this paper, the authors reveal why you need knowledge of drug potency, pharmacokinetics, and viral kinetics to guide rational use. Check it out to gain critical insights on how clinical pharmacology and model-based dosing can help maximize the likelihood of success for repurposing existing drugs for COVID-19 and future pandemics.